IFIH1 and interstitial lung disease: For example, muscle disease and arthritis are more common in patients with anti-Jo-1 antibodies (8), and tumors are more common in patients with anti-TIF1-γ (9); however, patients with anti-MDA5 autoantibodies can develop rapidly progressive ILD (2, 3, 5, 10), and their related mortality is very high.